Research Analysts Set Expectations for Minerva Neurosciences Inc’s FY2019 Earnings (NERV)

Share on StockTwits

Minerva Neurosciences Inc (NASDAQ:NERV) – Equities research analysts at Jefferies Financial Group issued their FY2019 earnings estimates for Minerva Neurosciences in a report issued on Tuesday, March 12th. Jefferies Financial Group analyst B. Amin anticipates that the biopharmaceutical company will post earnings of ($1.40) per share for the year. Jefferies Financial Group also issued estimates for Minerva Neurosciences’ FY2020 earnings at ($1.77) EPS, FY2021 earnings at ($1.50) EPS and FY2022 earnings at ($0.15) EPS.

Several other equities research analysts have also recently commented on NERV. ValuEngine cut shares of Minerva Neurosciences from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 18th. BidaskClub cut shares of Minerva Neurosciences from a “buy” rating to a “hold” rating in a research report on Thursday, December 20th. Finally, Zacks Investment Research cut shares of Minerva Neurosciences from a “buy” rating to a “hold” rating in a research report on Friday, January 4th.

NASDAQ:NERV opened at $8.25 on Friday. Minerva Neurosciences has a 12 month low of $5.80 and a 12 month high of $12.95. The stock has a market capitalization of $315.25 million, a PE ratio of -6.40 and a beta of 1.47.

Minerva Neurosciences (NASDAQ:NERV) last posted its earnings results on Tuesday, March 12th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by ($0.01).

Several institutional investors have recently modified their holdings of the stock. BlackRock Inc. increased its stake in shares of Minerva Neurosciences by 0.4% in the 4th quarter. BlackRock Inc. now owns 2,456,902 shares of the biopharmaceutical company’s stock worth $16,559,000 after acquiring an additional 8,576 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Minerva Neurosciences by 1.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,602,098 shares of the biopharmaceutical company’s stock valued at $10,798,000 after purchasing an additional 29,480 shares in the last quarter. Vanguard Group Inc. increased its stake in Minerva Neurosciences by 1.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,537,590 shares of the biopharmaceutical company’s stock valued at $19,297,000 after purchasing an additional 16,956 shares in the last quarter. Vanguard Group Inc increased its stake in Minerva Neurosciences by 1.1% during the 3rd quarter. Vanguard Group Inc now owns 1,537,590 shares of the biopharmaceutical company’s stock valued at $19,297,000 after purchasing an additional 16,956 shares in the last quarter. Finally, Millennium Management LLC increased its stake in Minerva Neurosciences by 5.9% during the 4th quarter. Millennium Management LLC now owns 1,251,680 shares of the biopharmaceutical company’s stock valued at $8,436,000 after purchasing an additional 69,859 shares in the last quarter. Institutional investors own 76.45% of the company’s stock.

In related news, CFO Geoff Race sold 5,999 shares of the stock in a transaction dated Monday, December 17th. The shares were sold at an average price of $7.46, for a total value of $44,752.54. Following the completion of the transaction, the chief financial officer now directly owns 204,369 shares in the company, valued at approximately $1,524,592.74. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last quarter, insiders sold 12,890 shares of company stock valued at $96,159. 9.60% of the stock is owned by company insiders.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.

Recommended Story: What factors cause inflation to rise?

Earnings History and Estimates for Minerva Neurosciences (NASDAQ:NERV)

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Research Analysts Set Expectations for Minerva Neurosciences Inc’s FY2019 Earnings
Research Analysts Set Expectations for Minerva Neurosciences Inc’s FY2019 Earnings
Vertex Pharmaceuticals  Stock Rating Upgraded by BidaskClub
Vertex Pharmaceuticals Stock Rating Upgraded by BidaskClub
PDC Energy  Lifted to Buy at BidaskClub
PDC Energy Lifted to Buy at BidaskClub
BidaskClub Downgrades Sunrun  to Hold
BidaskClub Downgrades Sunrun to Hold
Cloudera  Trading Down 19.8% After Earnings Miss
Cloudera Trading Down 19.8% After Earnings Miss
Semtech   Shares Down 6.3%  After Analyst Downgrade
Semtech Shares Down 6.3% After Analyst Downgrade


Leave a Reply

© 2006-2019 Ticker Report